Astellas Pharma (ALPMY) Stock Price, News & Analysis

Company Overview

Astellas Pharma Inc. is a global pharmaceutical company headquartered in Tokyo, Japan, with operations spanning North America, Europe, Asia-Pacific, Latin America and the Middle East. Formed in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has since established a solid presence in prescription drug research, development and commercialization. The company focuses on advancing therapies in oncology, urology, immunology, nephrology and neuroscience, aiming to deliver innovative solutions that address unmet medical needs.

Astellas’ product portfolio includes treatments for a wide range of conditions. Its oncology franchise features Xtandi (enzalutamide) for prostate cancer and PADCEV (enfortumab vedotin-ejfv) for urothelial cancer, both of which have become cornerstones of the company’s cancer pipeline. In urology, the company markets Myrbetriq (mirabegron) and Vesicare (solifenacin) to manage overactive bladder symptoms. Immunosuppressants such as Prograf (tacrolimus) and Astagraf XL also play key roles in the company’s offerings for organ transplant recipients.

Research and development is central to Astellas’ growth strategy. The company invests in next-generation modalities including gene therapy, cell therapy and targeted radiopharmaceuticals. Astellas maintains a network of research centers and partnerships worldwide to accelerate discovery and clinical trials, with a particular emphasis on precision medicine and regenerative solutions. This commitment to R&D has yielded a robust pipeline of investigational compounds across multiple therapeutic areas.

Under the leadership of President and CEO Naoki Okamura, Astellas aims to strengthen its global footprint and foster collaboration with academic institutions, biotech firms and healthcare providers. The management team emphasizes corporate responsibility, sustainability and patient-centric initiatives, ensuring that the company’s innovations contribute to better health outcomes and social value around the world.

Key Stats

• Today's Range: $9.46 to $9.72
• 50-Day Range: $9.12 to $9.93
• 52-Week Range: $8.37 to $13.14
• Volume: 83,023 shs
• Average Volume: 229,499 shs
• Market Capitalization: N/A
• P/E Ratio: 57.00
• Dividend Yield: 3.61%
• Price Target: N/A
• Consensus Rating: N/A

ALPMY Stock Analysis - Frequently Asked Questions

How have ALPMY shares performed this year?

Astellas Pharma's stock was trading at $9.66 on January 1st, 2025. Since then, ALPMY stock has increased by 0.3% and is now trading at $9.69.

How were Astellas Pharma's earnings last quarter?

Astellas Pharma Inc. (OTCMKTS:ALPMY) issued its quarterly earnings data on Friday, April, 25th. The company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of $0.15 by $0.12. The company earned $3.22 billion during the quarter, compared to analyst estimates of $3.02 billion. Astellas Pharma had a trailing twelve-month return on equity of 16.55% and a net margin of 2.65%.

When did Astellas Pharma's stock split?

Shares of Astellas Pharma split on the morning of Wednesday, April 2nd 2014.The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were distributed to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

Does Astellas Pharma have any subsidiaries?

The following companies are subsidiaries of Astellas Pharma: Iota Biosciences, Nanna Therapeutics, Xyphos, Audentes Therapeutics, Potenza Therapeutics, Quethera, Universal Cells Inc., and others.

How do I buy shares of Astellas Pharma?

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 4/25/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 7/29/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ALPMY
• CIK: 1446390
• Web: www.astellas.com
• Phone: (133) 244-3000
• Fax: N/A
• Employees: 14,754
• Year Founded: 1923

Profitability

• EPS (Trailing Twelve Months): $0.17
• Trailing P/E Ratio: 57.00
• Forward P/E Ratio: 23.07
• P/E Growth: N/A
• Net Income: $334.93 million
• Net Margins: 2.65%
• Pretax Margin: 1.63%
• Return on Equity: 16.55%
• Return on Assets: 7.35%

Debt

• Debt-to-Equity Ratio: 0.37
• Current Ratio: 1.13
• Quick Ratio: 0.85

Sales & Book Value

• Annual Sales: $12.56 billion
• Price / Sales: N/A
• Cash Flow: $1.81 per share
• Price / Cash Flow: 5.36
• Book Value: $5.52 per share
• Price / Book: 1.76

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.23